XyloCor Therapeutics is a biopharmaceutical company focused on developing gene therapy for advanced coronary artery disease.

XyloCor Therapeutics

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

Sofinnova Investments

Fountain Healthcare Partners

EQT life science

Longwood Fund

Lumira Ventures

XyloCor Therapeutics, Inc.

Today our CEO Al Gianchetti was interviewed by Ali Gorman of BiotechTV and they discussed the exciting progress XyloCor is making with the clinical development of XC001 for patients with refractory angina. In addition, they discussed XyloCor's recent agreement with SmartCella which enables XyloCor to use their Extroducer catheter (use the title from the press release) to deliver XC001 to the heart without the need for a surgical procedure. 
#Philly #biotech #cardiovascular #genetherapy
https://lnkd.in/g_ADHVMV

#NEWS: Today, we announced an agreement with Smartwise , a unit of SmartCella Holding AB (“SmartCella”). We have entered into a licensing agreement under which XyloCor has rights to the Extroducer® Infusion Catheter System ®, a first-in-class endovascular device designed to deliver advanced therapies directly into the heart [and hard-to-reach tissues]. XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of its lead gene therapy candidate, XC001 (encoberminogene rezmadenovec), in future clinical studies and commercial use. 
Read more here: https://lnkd.in/edyPaxJy   
 #GeneTherapy #HeartDisease #Innovation #cardiovascular

Thank you to Laurie Glimcher, Ivana Magovcevic-Liebisch, PhD, JD, Maria Whitman, Al Gianchetti & Brian Alexander for the important #patientcentricity discussion #longwoodhealthcareleaders Longwood Fund

#NEWS: Today, we announced positive Phase 2 data for our refractory angina treatment candidate, a novel therapeutic approach that aims to fill a significant unmet medical need for people who have exhausted available treatment options and have a debilitating quality-of-life. Our #clinicaltrial results were also presented today at the  Society for Cardiovascular Angiography & Interventions 2024 Scientific Sessions and will be published in the medical journal Circulation: Cardiovascular Interventions. Read more here: https://lnkd.in/edyPaxJy  
#SCAI2024
 #GeneTherapy #HeartDisease #Innovation

Happy Holidays from the XyloCor family to yours.

Metric
Company Name	XyloCor Therapeutics
Symbol
MSH ID	COM:XYLOCOR
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	18
Website	xylocor.com
LinkedIn	xylocor-therapeutics-inc.
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

XYLO

COM:XYLOCOR

XyloCor Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue